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Introduction
Coronary artery disease and myocardial infarctions are the major cause of death in the industrialized world (www.who.org). Current treatments, such as percutaneous angioplasty and bypass surgery, focus on the relieving of the ischaemia, reducing ongoing tissue damage, rather than on tissue regeneration. This warrants investigation into new strategies for the treatment of ischaemic diseases.
Regenerative medicine aims to maintain, improve or restore tissue function by employing the bodies' own regenerative mechanisms. An example is cell therapy, which is an experimental strategy for the treatment of ischaemic diseases, such as myocardial infarction. Herein, neovascularization induced by progenitor cells is an essential factor and has been a topic of intense research over the past decade. The rare CD34 ϩ stem cell is often designated as the endothelial progenitor cell (EPC), as it contributes to repair of vascular damage in vivo. However, incorporation of CD34 ϩ cells into the neovasculature is limited [1] [2] [3] [4] . We, and others, have shown that in vivo neovascularization relies on a paracrine function of human CD34 ϩ cells, which involves recruitment of monocytes, rather than actual incorporation [5, 6] among others.
In a mouse model of myocardial infarction, we have shown that ischaemic tissue damage leads to the recruitment of bone marrow derived progenitor cells and monocytes to the damaged site, which is a prerequisite for repair. These bone marrow derived cells also differentiate, to myofibroblasts and thus contribute to wound healing [7] . Furthermore, the recruited monocytes were shown to influence neovascularization and remodelling after myocardial infarction, as depletion of these cells from the circulation resulted in decreased neovascularization and impaired remodelling of the myocardial infarction [8] . In vitro, we have shown that human monocytes, i.e. CD14 ϩ cells, differentiate into functional endothelial cells [9] . As a consequence of this ability, these CD14 ϩ cells are often referred to as 'early EPC' [10] , 'colony forming unitendothelial cell (CFU-EC)' [11, 12] or 'endothelial-like cells' [9, 13] . Thus, differentiated CD14 ϩ cells may contribute to neovascularization in vivo and to remodelling of the infracted area. These data suggest that both CD34 ϩ cells and CD14 ϩ cells play a key role in the repair and regeneration in cardiovascular and ischaemic diseases. We made the assumption that circulating EPCs, i.e. CD34 ϩ cells, and CD14 ϩ cells interact during neovascularization and that paracrine signalling of CD34 ϩ cells augments endothelial cell differentiation of the CD14 ϩ cells. We examined the interaction between CD34 ϩ cells and CD14 ϩ cells and the effect on endothelial cell differentiation and cell proliferation in vitro. To this end, these cells were co-cultivated and the expression of endothelial cell markers was evaluated. Additionally, the (paracrine) factors that drive the endothelial cell differentiation and proliferation were investigated. Finally, the functionality of the newly differentiated endothelial cells was assayed in vitro.
Materials and methods

Cell isolation and culture
Peripheral blood mononuclear cells (pbMNC) were isolated from buffy coats from healthy donors (Sanquin, Groningen, the Netherlands) using density gradient centrifugation on lymphoprep (Nycomed Pharma, Roskilde, Norway). CD34 ϩ cells were isolated by magnetic bead separation and further purified by fluorescence-activated cell sorting (FACS) as described previously [6] . Subsequently, monocytes, i.e. CD14 ϩ cells, were isolated from the remaining MNC-fraction by magnetic bead separation as described previously [9] . Flow cytometric analysis revealed an average purity of 98 [14] ), 10 ng/ml basic fibroblast growth factor (bFGF) and 1 ng/ml vascular endothelial growth factor (VEGF)-A (both Peprotech, Rockhill, NJ, USA). Culture medium was refreshed every third day. 
Colony forming unit-endothelial cell assays
Endothelial cell marker analysis
Thrombin generation assays and sprout formation
To assess their endothelial cell function, cultured cells were assayed for their ability to inhibit factor-3-dependent thrombin formation. To this end, a Thrombin Generation Assay (HaemoScan, Groningen, The Netherlands) was used. In brief, mono-and co-cultured cells were dissociated by accutase treatment and replated at a density of 50,000 cells/cm 2 on fibronectin/gelatin-coated culture wells subsequently. After overnight culture, the culture medium was removed and replaced by fibrinogen-depleted human plasma. During this incubation the intrinsic coagulation cascade is activated. Thereafter, the clotting cascade was further activated by addition of a mixture of 30 mM CaCl2 and phospholipids, which results in the generation of thrombin. Samples were taken at regular intervals and added to ice-cold 25 mM TrisHCl to prevent any further thrombin generation. Finally, the diluted samples were incubated with 3 mM thrombin substrate S2238. Thrombin releases p-nitroaniline chromophore from the substrate, which results in a change of colour. The change in colour was measured at 405 nm with 540 nm as reference wavelength in a microtitre plate reader (BioRad, Hercules, VA, USA). A calibration curve of known thrombin concentrations was used to quantify the thrombin formation in the experimental samples. Human umbilical vein endothelial cells (HUVEC) and factor-3 positive vascular smooth muscle cells (VSMC) were used as negative and positive controls, respectively. The ability to form capillary-like sprouts was investigated using a Matrigel Sprouting Assay (BD Biosciences). After 21 days of culturing, monocultured and co-cultured cells were dissociated using accutase and plated on Matrigel (BD Biosciences) coated wells at a density of 250,000 cells/cm 2 and cultured in endothelial cell medium for an additional 24 hrs. The formation of capillary-like structures was analysed using regular light microscopy.
Cytokine and growth factor secretion
At days 0, 3, 7 and 21 of culture, culture medium was sampled. The concentration of cytokines angiopoietin (ANG)-2, interleukin (IL)-8, monocyte chemoattractant protein (MCP)-1 and tumour necrosis factor-␣ (TNF-␣) as well as growth factors epidermal growth factor (EGF), bFGF, hepatocyte growth factor (HGF), transforming growth factor-␤ (TGF-␤) and VEGFa were determined using multiplex protein analysis by PerBio Sciences (Cramlington, UK).
At day 3, total RNA was isolated from CD34 ϩ cell monocultures or CD14 ϩ cell monocultures using an RNeasy Micro Kit (Qiagen, Valencia, CA, USA) following manufacturer's instructions. RNA integrity was determined by gel electrophoresis and RNA purity and concentration were determined using Nanodrop equipment (Nanodrop Technologies, Wilmington, NC, USA). Subsequently, 100 ng RNA was reverse transcribed using a First Strand cDNA synthesis Kit (Fermentas UAB, Vilnius, Lithuania). One micro litre cDNA was used for amplification in 384-well microtitre plates in a TaqMan ABI7900HT cycler (Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 10 l containing 5 l TaqMan universal PCR Master Mix (Applied Biosystems) and 0.5 l primer/probe mix. Applied Biosystems 'assay on demand' primer/probe sets were used to detect amplimers of ␤-2-Microglobulin (␤2M; Hs99999907_m1), IL-8 (Hs00174103_m1), MCP-1 (Hs00234140_m1) and HGF (Hs00300159_m1). Cycle threshold (CT) values for individual reactions were determined using ABI Prism SDS 2.2 data processing software (Applied Biosystems). To determine differences in gene transcripts between CD34 ϩ cells and CD14 ϩ cells CT-values were normalized against ␤2M using the ⌬CT-method (⌬CT(gene) ϭ CT(gene) -CT(␤2M)). To correct for interassay variance, ⌬CT values were normalized against expression levels of an external calibrator (⌬⌬CT(gene) ϭ ⌬CT(gene) -⌬CT(calibrator)). Fold variance in transcript levels between CD34 ϩ cells and CD14 ϩ cells were calcu-
All cDNA samples were amplified in triplicate and RNA controls were included to test for primer binding to genomic DNA. Differences of twofold higher or greater were considered to be biologically relevant.
Conditioned medium cultures
To assess the influence of paracrine factors produced during co-cultivation, conditioned medium cultures were performed. Briefly, CD14 ϩ cells were plated in fibronectin/gelatin-coated wells at a density of 250,000 cells/cm 2 . Every third day, culture medium was removed from cells in mono-or in co-culture. Conditioned culture medium from different donors was pooled to reduce donor variation and sterilized by filtration through a 0.2-m filter. Plated monocytes were cultured in conditioned culture medium supplemented with excess neutralizing goat antibodies to either human HGF, IL-8, MCP-1 or mock goat IgG (all 200 ng/ml medium; all R&D Systems). Conditioned medium and antibodies were refreshed every third day. After 21 days of culture, cells were dissociated using accutase and stained for protein expression of CD31, vWF, CD144 and eNOS. Protein expression of these endothelial cell markers was analysed by FACS analysis as described above. Inhibition of endothelial cell differentiation by neutralizing antibodies was calculated as the fraction of differentiation decrease by the neutralizing antibodies in relation to the mock IgGs according to the following equation:
Statistical analysis
Data are presented as mean Ϯ S.E. of the mean. Data in Gaussian distribution are analysed by two-factor ANOVA followed by Tuckey post hoc analysis. All other data were analysed using Mann-Whitney tests. Probabilities lower than P Ͻ 0.05 were considered to be statistically significant. 
Results
Phenotypes of CD34 ϩ cells and CD14
Colony forming unit-endothelial cells
Human pbMNC, containing fluorescently labelled CD34 ϩ cellsand CD14 ϩ cells were cultured under angiogenic conditions. Colonies had formed after 7 days of culturing ( Fig. 1A) .
Examination of the CFU-ECs by immunofluorescence microscopy revealed that these CFU-ECs consisted mainly of CD14 ϩ -derived cells ( Fig. 1B; red cells) and that CD34 ϩ -derived cells (green cell) co-localized with CD14 ϩ -derived cells in these CFU-ECs (Fig. 1B) . Although CD34 ϩ -derived cells were also found outside the CFU-ECs, colonies lacking CD34 ϩ -derived cells were almost never observed. Analysis of outgrowth endothelial colonies by transmission electron microscopy also showed co-localization and cell-cell contacts (arrows) of cells with progenitor cell morphology ( Fig. 1C and D; small-round cells) and cells with endothelial cell morphology (elongated cells). Cultured cells with an endothelial-like morphology, i.e. spindle-shaped cells, were quantified after 14 days ( Fig. 1E and F 
Endothelial cell marker expression
Protein expression of endothelial cell markers was determined by immunofluorescent stainings ( Fig. 2A and B ) and FACS analysis for CD14, CD31, VEGFR-2, vWF, CD144 and eNOS ( Fig. 2C and D and Table 2 ). CD34 ϩ cells in monoculture hardly ever expressed endothelial cell markers. Although over 30% of CD34 ϩ cells did express CD31 (Table 2) , co-expression of CD31 and vWF was almost never observed. In fact, only 6-9% of the CD34 ϩ cells showed signs of endothelial cell differentiation by the combined expression of either CD31 and vWF or CD144 and eNOS. In contrast, CD14 ϩ cells in monoculture efficiently differentiated into an endothelial cell phenotype. CD14 ϩ cell-derived endothelial cells lost their expression of monocyte marker protein CD14, which decreased from 99.80 Ϯ 0.10% (day 1) to 12.53 Ϯ 2.54% (day 21; Table 2 ). Over 60% of the CD14 ϩ cells had acquired a CD31 ϩ vWF ϩ phenotype and a CD144 ϩ eNOS ϩ phenotype (Fig. 2C) .
Interestingly, endothelial cell differentiation was significantly increased in all the co-cultures, where over 85% of cells acquired the CD31 ϩ vWF ϩ phenotype (P Ͻ 0.01 versus CD14 ϩ cells) and over 90% of cells acquired the CD144 ϩ eNOS ϩ phenotype (P Ͻ 0.001 versus CD14 ϩ cells). Expression of VEGFR-2 was present on the CD14 ϩ cells at the start of culture and did not change during the mono-or co-culture time ( Table 2 ). Expression of all endothelial cell markers by co-cultured cells was not different from HUVEC and was similar in all co-cultures (Fig. 2C ).
Cell proliferation
Proliferation of cultured cells was assessed by staining of nuclear antigen Ki67 at day 21 ( Fig. 3A and B) . In the monocultures containing either CD34 ϩ cells or CD14 ϩ cells, no or limited proliferation was observed (Fig. 3C ). CD34 ϩ monocultures did not proliferate at all, and only 1.13 Ϯ 0.24% of the CD14 ϩ cells in monoculture stained positive for Ki67. The co-cultured cells in the ratio of CD34 (1:100) CD14 and CD34 (1:1000) CD14 showed significantly higher proliferation rates (10.70 Ϯ 1.02% and 9.20 Ϯ 1.14%, respectively, P Ͻ 0.01) than the CD14 ϩ cells in monoculture. The coculture of CD34 (1:10) CD14 also showed higher proliferation rates (6.01 Ϯ 1.37%, P Ͻ 0.05) than the CD14 ϩ cells in monoculture did, but proliferation in the CD34 (1:10) CD14 co-culture was lower than in the other two co-cultures (P Ͻ 0.05). At no time, proliferation was observed in the monocultures (data not shown). 
Endothelial cell function
To assess the functionality of the cultured cells, their ability to prevent factor 3-dependent thrombin formation was determined (Fig. 4A) . co-culture tended to be higher throughout the 21-day culture period (P Ͻ 0.10; see online data supplement). Background levels of HGF (40.3 Ϯ 5.8 pg/ml), IL-8 (289.9 Ϯ 174.9 pg/ml) and MCP-1 (105.4 Ϯ 55.2 pg/ml) were detected at the start of culture. In contrast to the growth factors and cytokines described above, significant increases in the concentrations of these factors were observed (Fig. 5 ). The concentration of HGF increased most rapidly in the CD34 ϩ monoculture, where HGF concentration reached 11,202 Ϯ 5421 pg/ml (ഠ270-fold increase) at day 3 (Fig. 5A) . By then, the concentration of HGF protein in the CD34 ϩ monoculture was significantly higher than in the CD14 ϩ monoculture (405.9 Ϯ 68.4 pg/ml, P Ͻ 0.05) and the CD34 (1:100) CD14 co-culture (408.7 Ϯ 73.5 pg/ml, P Ͻ 0.05). Concentrations of HGF protein in the CD14 ϩ monoculture and in the CD34 (1:100) CD14 co-culture also increased during culture. HGF concentration reached a maximum of over 10,000 pg/ml in all cultures at day 21.
Fig. 1 Formation of endothelial outgrowth colonies and cells. Peripheral blood MNC form colony forming unit-endothelial cells (CFU-ECs) after angiogenic stimulation (A). Within these colonies, CD34 ϩ cells (green cell) and CD14 ϩ cells (red cells) co-localize (B). At the sites of endothelial cell formation, cell-cell contacts (arrows) are formed between cells with progenitor cell-(small round) and endothelial cell (spindleshaped) morphology (C). At day 14, spindle-shaped cells (D, arrows) originating from these CFU-ECs are mainly derived from the CD14 ϩ cells (E).
Cytokine and growth factor secretion
Concentrations of IL-8 and MCP-1 also showed a more rapid increase in the CD34 ϩ monoculture compared to the CD14 ϩ monoculture and the CD34 (1:100) 
To examine if differences in protein concentrations of HGF, IL-8 and MCP-1 were related to differences in gene expression between CD34 ϩ cells and CD14
ϩ cells in monoculture, we performed transcriptome analysis (Fig. 5D) . At day 3 of culture, CD34 ϩ cells in monoculture had a higher gene transcript level for both MCP-1 (9-fold) and HGF (7-fold) compared to CD14 ϩ cells in monoculture, but there was no biologically relevant difference in gene expression of IL-8 (Ͻ2-fold).
Conditioned medium cultures
To assess the effects of paracrine factors, CD14 ϩ cells were cultured in the presence of conditioned culture media. Thereafter, expression of endothelial cell markers CD31, vWF, CD144 and eNOS was assessed by FACS analysis. Endothelial cell differentiation of monocultured CD14 ϩ cells was approximately 63% (Fig. 6A  and B ) and did not change by addition of conditioned medium from CD14 ϩ cells. In fact, the co-expression of CD144 and eNOS was decreased to approximately 40% (P Ͻ 0.01; Fig. 6B ). In contrast to the CD14 ϩ cells conditioned medium, exposure to conditioned media from either CD34 ϩ cells in monoculture, or CD34 ϩ /CD14 ϩ co-cultures, significantly increased endothelial cell differentiation by CD14 ϩ cells (Fig. 6A and B) . Co-expression of endothelial cell markers CD31 and vWF increased from 63% for CD14 ϩ cells in monoculture to over 95% in all the CD34 ϩ cellsderived conditioned media ( Fig. 6A; P Ͻ 0.05) . Similarly, the co-expression of endothelial cell markers CD144 and eNOS increased from 63% for CD14 ϩ cells in monoculture to over 95% in all the CD34 ϩ cells-derived conditioned media ( Fig. 6B ; P Ͻ 0.001). Neutralizing antibodies to HGF, IL-8 and MCP-1 were added to the conditioned medium in order to determine their influence on the increased endothelial cell differentiation. Neutralizing antibodies to HGF reduced the effect of the conditioned culture media by 30-60% ( Fig. 6C and D) . Co-expression of endothelial cell markers CD31 and vWF was reduced by over 30% (P Ͻ 0.05) both in the CD34 ϩ and in the CD14 ϩ cells conditioned medium (Fig. 6C) . In contrast, HGF neutralizing antibodies added to CD14 ϩ cell conditioned medium did not decrease co-expression of CD144 and eNOS (P ϭ 0.24). Co-expression of CD144 and eNOS, however, was reduced by approximately 50% when HGF neutralizing antibodies were added to CD34 ϩ /CD14 ϩ cell conditioned media (P Ͻ 0.05; Fig. 6D ). A trend for decreased co-expression of CD144 and eNOS was found when HGF neutralizing antibodies were added to CD34 ϩ cells conditioned media (P ϭ 0.057), but did not reach statistical significance. Addition of neutralizing antibodies to either IL-8 or MCP-1 did not alter the co-expression of CD31 and vWF and CD144 and eNOS (see online data supplement).
Addition of recombinant human HGF to CD14 ϩ cells in monoculture increased endothelial cell differentiation of CD14 ϩ cells, as determined by co-expression of CD31 and vWF (Fig. 6E ). The increase in endothelial cell differentiation caused by the addition of HGF was dose-dependent and had an EC50 of 11.09 Ϯ 2.12 ng/ml.
Discussion
Current gold standard cardiovascular therapies, such as percutaneous angioplasty and stenting, focus on the prevention of acute and ongoing tissue damage by relieve of the ischaemia, rather than on tissue regeneration. Therefore, tissue regeneration by stem cell therapy is a promising new treatment strategy to treat ischaemic diseases, such as myocardial infarction. However, cell therapy strategies that use peripheral blood derived progenitor cells as a source of EPCs have been hampered by low cell numbers, lack of cell proliferation and the absence of cellular contribution to the neovasculature. In this study, we have shown that (1) Although the CD34 ϩ stem cell has been regarded as the archetype EPC, its cellular incorporation into the neovasculature is hardly observed [2] [3] [4] . In fact, there is a growing body of literature showing that endothelial-like cells of monocytic (i.e. CD14 ϩ ) origin influence neovascularization [6, [15] [16] [17] [18] [19] . We have previously shown that monocyte depletion results in reduced neovascularization of ischaemic areas after myocardial infarction [8] . Furthermore, data from both animal experiments and clinical trials suggest that the CD34 ϩ cell augments neovascularization and endothelial cell differentiation in a paracrine manner, rather than by incorporation into the neovasculature [4] [5] [6] [20] [21] [22] [23] [24] . In addition, Bonello et al. reported increased numbers of circulating CD14 ϩ cells after angioplasty-induced endothelial cell damage [25] . These circulating CD14 ϩ cells may be mobilized by increased levels of HGF after angioplasty [26] and help to repair the injured endothelium [16, 27] by mechanisms described here.
Here we aimed to investigate the interaction between CD34 ϩ cells and CD14 ϩ cells in vitro. We have shown that the culture of pbMNC results in a co-localization of CD34 ϩ -derived cells and CD14 ϩ -derived cells (Fig. 1) . Similarly, Yoon et al. showed that early endothelial cell outgrowth colonies comprised of CD14 ϩ monocytic cells and CD14 Ϫ cells [19] . As shown in Fig. 1, we 
in a recent study showed that interaction of CD14 ϩ cells with T lymphocytes was accountable for the formation of these CFU-ECs in vitro [28]. However, the influence of T lymphocytes on endothelial cell differentiation was not investigated. This suggests that T cells, in combination with CD14 ϩ cells and CD34 ϩ cells form a microenvironment, i.e. the CFU-ECs, in which differentiation of primitive CD14 ϩ cells towards an endothelial cell lineage is instructed.
In agreement with our finding that co-cultivation of CD34 ϩ cells and CD14 ϩ cells results in increased endothelial cell differentiation in vitro (Fig. 2) , Yoon et al. showed increased endothelial cell differentiation in vitro and increased progenitor cell incorporation into the neovasculature when a mixture of CD14 ϩ cells and CD34 ϩ cells were co-injected into ischaemic hind limbs of nude mice [19] . Similarly, in vivo co-localization of CD14 ϩ cells and CD34 ϩ cells at sites of active neovascularization and endothelial cell differentiation was reported by Anghelina et al. and Moldovan et al. [15, 29, 30] . Co-cultivation did not only result in increased expression of endothelial cell markers by CD14 ϩ cells, but also in gain of endothelial cell functionality. In concurrence with the work of Smadja et al. who reported that umbilical cord EPC have anticoagulant effects [31] , we show that CD14 ϩ cell-derived endothelial cells actively inhibit thrombin formation in an in vitro coagulation assay ( Fig. 4) and thus can influence haemostasis.
Besides increased differentiation of functional endothelial cells, we show that co-cultivation of CD34 ϩ cells and CD14 ϩ cells results in increased proliferation of the CD14 ϩ cells (Fig. 3) . In agreement with other studies, we found that monocultured CD14 ϩ cells proliferate only scarcely [9, 13, [32] [33] [34] . However, when cultured in the presence of CD34 ϩ cells, proliferation increased to approximately 10% at week 3 indicating differentiation of long-lived CD14 ϩ cell-derived endothelial cells. Although higher levels of proliferation by CD14 ϩ cells in pre-differentiation cultures have been described [35] [36] [37] , only few reports describe the differentiation of a functional and proliferating endothelial cell population originating from CD14 ϩ cells. Our finding that functional and proliferating endothelial cells can be differentiated from CD14 ϩ cells, corroborates the findings of Elsheikh et al. and Romagnani et al. [38, 39] .
To assess whether the increase in endothelial cell differentiation and proliferation depends on cell-cell adhesions, we performed differentiation experiments using conditioned culture media from CD34 ϩ and CD14 ϩ monocultures. Although cell-cell adhesions were identified between cells with an endothelial celland with progenitor cell-morphology ( Fig. 1) , CD34 ϩ cells conditioned culture media displayed a similar increase in endothelial cell differentiation as seen in CD34 ϩ /CD14 ϩ cells in co-culture (comparison Figs 2 and 6) . Therefore, we conclude that CD34 ϩ cells influenced the differentiation of CD14 ϩ cells in a paracrine manner. This paracrine effect of CD34 ϩ cells has been suggested previously. More precise, we and others have described the secretion of pro-angiogenic factors, such as MCP-1, IL-8, VEGF and bFGF [4] [5] [6] [20] [21] [22] [23] [24] , by CD34 ϩ cells both in vitro and in vivo, rather than endothelial cell differentiation and incorporation into the neovasculature by that same cell type. Analysis of conditioned culture media revealed large increases in secreted IL-8, MCP-1 and HGF during a 3-week culture period. Notably, the gene transcripts of these factors were present at a higher level in CD34 ϩ cells than in CD14 ϩ cells, and the extracellular concentrations of these pro-angiogenic factors increased faster in the CD34 ϩ cells culture media than in CD14 ϩ cell conditioned media or the CD34 ϩ /CD14 ϩ co-culture media (Fig. 5 ). This suggests that these factors are actively taken up by the CD14 ϩ cells and used during downstream signalling cascades. Therefore, we investigated the effects of these factors on endothelial cell differentiation by CD14 ϩ cells using neutralizing antibodies against IL-8, MCP-1 and HGF. IL-8 and MCP-1 have been described as angiogenic cytokines. In this context, IL-8 and MCP-1 were associated with the recruitment and migration of CD14 ϩ cells [6, 29, [40] [41] [42] [43] , CD14 ϩ cell adhesion [16] , growth factor secretion [44] [45] [46] and endothelial cell proliferation [47] . Although IL-8 and MCP-1 are involved in the induction of angiogenesis and cell recruitment, we did not observe inhibition of endothelial cell differentiation by IL-8 nor MCP-1 neutralizing antibodies in vitro (see online data supplement). This suggests that IL-8 and MCP-1 act at a different level on CD14 ϩ cells during neovascularization, other than endothelial cell differentiation. In contrast, neutralizing antibodies to HGF did decrease endothelial cell differentiation by CD14 ϩ cells and addition of HGF to CD14 ϩ cells in monoculture did increased endothelial cell differentiation of these cells in a dose-dependent manner (Fig. 6 ). Our observation in vitro appears to be supported by in vivo data of Cai et al. who showed that HGF is an obligatory molecule for revascularization of ischaemic tissue [48] . Furthermore, Bordoni et al. have shown that hepatocyte-conditioned medium was able to influence endothelial cell differentiation by EPC in vitro [49] . These findings support our finding that indeed HGF is involved in endothelial cell differentiation by CD14 ϩ cells.
In summary, we show that co-cultivation of CD34 ϩ cells and CD14 ϩ cells results in increased differentiation of human CD14 ϩ cells towards functional and proliferating endothelial cells in vitro. The increased differentiation and proliferation were dependent on paracrine signalling through HGF, rather than on cell-cell contacts. Taken together, the combination of CD14 ϩ cells and CD34 ϩ cells yields a proliferating population of endothelial cells that may be a suitable cell source that can be applied as cell therapeutic for treatment of cardiovascular diseases, and can augment therapeutic neovascularization in various disease models.
